Thermo Fisher ScientificTMO
TMO
About: Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year end-2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (54%).
Employees: 125,000
0
Funds holding %
of 7,419 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
39% more first-time investments, than exits
New positions opened: 277 | Existing positions closed: 200
1.37% more ownership
Funds ownership: 86.77% [Q3] → 88.14% (+1.37%) [Q4]
1% more funds holding
Funds holding: 2,531 [Q3] → 2,553 (+22) [Q4]
13% less capital invested
Capital invested by funds: $204B [Q3] → $177B (-$26.9B) [Q4]
19% less repeat investments, than reductions
Existing positions increased: 870 | Existing positions reduced: 1,070
27% less call options, than puts
Call options by funds: $1.06B | Put options by funds: $1.44B
37% less funds holding in top 10
Funds holding in top 10: 115 [Q3] → 72 (-43) [Q4]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$475
10%
upside
Avg. target
$619
43%
upside
High target
$715
66%
upside
7 analyst ratings
4 positive
57%
3 neutral
43%
0 negative
0%
Wells Fargo Brandon Couillard 24% 1-year accuracy 6 / 25 met price target | 34%upside $580 | Overweight Maintained | 17 Apr 2025 |
Barclays Luke Sergott 21% 1-year accuracy 12 / 58 met price target | 10%upside $475 | Equal-Weight Maintained | 10 Apr 2025 |
Citigroup Patrick Donnelly 19% 1-year accuracy 6 / 31 met price target | 32%upside $570 | Neutral Maintained | 4 Mar 2025 |
Scotiabank Sung Ji Nam 4% 1-year accuracy 1 / 24 met price target | 51%upside $650 | Sector Perform Maintained | 3 Feb 2025 |
Raymond James Andrew Cooper 0% 1-year accuracy 0 / 16 met price target | 55%upside $667 | Outperform Reiterated | 3 Feb 2025 |
Financial journalist opinion
Based on 25 articles about TMO published over the past 30 days
Positive
Zacks Investment Research
17 hours ago
Thermo Fisher's Q1 Earnings Top Estimates, Revenues Beat, Stock Up
TMO continues to advance its growth strategy and trusted partner status with customers in the first quarter of 2025.
Positive
Benzinga
18 hours ago
Thermo Fisher Scientific Q1 Earnings Surpass Estimates, CEO Touts 'Strong Performance' Despite Economic Uncertainty
Thermo Fisher Scientific Inc. TMO reported first-quarter 2025 adjusted earnings per share of $5.15 on Wednesday, beating the street view of $5.10.
Positive
Investopedia
19 hours ago
Thermo Fisher Tops Q1 Estimates in 'Uncertain Macroeconomic Environment'
Thermo Fisher Scientific (TMO) shares rose Wednesday after the lab equipment and life science solutions firm reported first-quarter results above analysts' expectations.
Neutral
Seeking Alpha
19 hours ago
Thermo Fisher Scientific Inc. (TMO) Q1 2025 Earnings Call Transcript
Thermo Fisher Scientific Inc. (NYSE:TMO ) Q1 2025 Earnings Conference Call April 23, 2025 8:30 AM ET Company Participants Rafael Tejada - Vice President, Investor Relations Marc Casper - Chairman, President & Chief Executive Officer Stephen Williamson - Senior Vice President & Chief Financial Officer Conference Call Participants Michael Ryskin - Bank of America Matt Sykes - Goldman Sachs Jack Meehan - Nephron Research Rachel Vatnsdal - JPMorgan Doug Schenkel - Wolfe Research Tycho Peterson - Jefferies Operator Good morning, ladies and gentlemen, and welcome to the Thermo Fisher Scientific 2025 First Quarter Conference Call. [Operator Instructions] I would like to introduce our moderator for the call, Mr.
Neutral
Zacks Investment Research
20 hours ago
Thermo Fisher (TMO) Reports Q1 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Thermo Fisher (TMO) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Positive
Zacks Investment Research
22 hours ago
Thermo Fisher Scientific (TMO) Q1 Earnings and Revenues Beat Estimates
Thermo Fisher Scientific (TMO) came out with quarterly earnings of $5.15 per share, beating the Zacks Consensus Estimate of $5.10 per share. This compares to earnings of $5.11 per share a year ago.
Neutral
Seeking Alpha
23 hours ago
Buckle Up Buttercup - Here's What Every (Dividend) Investor Needs To Hear Right Now
Trade uncertainty, Fed drama, and stretched valuations are driving a powerful capital rotation away from U.S. assets, impacting the dollar, debt, and equities. Despite headwinds, I remain confident in the structural strengths of the U.S. economy, emphasizing value stocks and real businesses over market noise. The U.S. still offers some of the best investment opportunities, particularly in value and dividend stocks, even as global investors seek international value.
Positive
Reuters
23 hours ago
Thermo Fisher beats estimates on steady demand for tools and services used in clinical research
Thermo Fisher Scientific reported better-than-expected profit and revenue for the first quarter on Wednesday, helped by resilient demand for its products and services used for developing therapies.
Neutral
Business Wire
1 day ago
Thermo Fisher Scientific Reports First Quarter 2025 Results
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended March 29, 2025. First Quarter Highlights First quarter revenue was $10.36 billion. First quarter GAAP diluted earnings per share (EPS) grew 15% to $3.98. First quarter adjusted EPS grew 1% to $5.15. Delivered very strong financial performance in the quarter, demonstrating the strength of our trusted partner status and t.
Positive
Seeking Alpha
3 days ago
2 Of The Biggest Dip Opportunities In Dividend (Growth) Land
Market fear creates hesitation, but history shows scary headlines often mark great buying opportunities. I assess risk, not just wait for perfect timing. My strategy to rotate from growth to value has helped me outperform. I bought quality dividend growers when panic set in, based on logic, not luck. I highlight two compelling stocks: one a powerful long-term grower in healthcare, the other a higher-yielding pick tied to industrial strength and income stability.
Charts implemented using Lightweight Charts™